MarkGregoryGarzottoMD

Urology • Portland, OR

Professor, Urology and Radiation Oncology, OHSU, Chief of Urology, Portland VA Medical Center

Join to view full profile

Dr. Garzotto is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Garzotto's full profile

Already have an account?

Office
3181 SW Sam Jackson Park Rd
Portland, OR 97239
Phone+1 503-494-7760

Fax+1 503-346-1501

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Urologic Surgical Oncology, 1995 - 1999
University of FloridaResidency, Urology, 1992 - 1995
University of FloridaResidency, Surgery, 1990 - 1992
Louisiana State University School of Medicine in New OrleansClass of 1990

Certifications & Licensure

OR State Medical License 2000 - 2025
NY State Medical License 1995 - 2000
FL State Medical License 1992 - 1998
LA State Medical License 1990 - 1990
American Board of Urology Urology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma Start of enrollment: 2006 Jun 01
Completed
Phase 3
S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Start of enrollment: 2006 Aug 01
Completed
Phase 3
Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer Start of enrollment: 2006 Jan 31
Active, not recruiting
Phase 1, Phase 2
Statin Therapy Versus Placebo Prior to Prostatectomy Start of enrollment: 2007 Dec 01
Completed
Not Applicable
Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA Methylation Start of enrollment: 2011 Jul 01
Completed
Not Applicable
Magnetic Resonance Spectroscopic Imaging Study of Prostatic Fats to Distinguish the Difference Between High and Low Risk Prostate Cancer Start of enrollment: 2013 Jan 01
Completed
Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer Start of enrollment: 2018 Dec 03
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Safety and Efficacy of Neoadjuvant Docetaxel and Radiotherapy in Localized High-Risk Prostate Cancer: Results From a Prospective Pilot Study.
Kim C Ohaegbulam, Carl M Post, Paige E Farris, Mark Garzotto, Tomasz M Beer
American Journal of Clinical Oncology. 2024-10-30
Corrigendum to "Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Onc...
Oliver Sartor, Theodore G Karrison, Howard M Sandler, Leonard G Gomella, Mahul Amin
European Urology. 2024-09-01
1 citations
BMI and BPH correlate with urinary microbiome diversity and lower urinary tract symptoms in men.
Kate R Bowie, Mark Garzotto, Eric Orwoll, Lisa Karstens
Biorxiv. 2023-12-15

Press Mentions

Polygenic Risk Score May Be Useful in Prostate Cancer Active SurveillanceJanuary 2nd, 2025
Exercise During Prostate Cancer Active Surveillance May Improve CV Risk FactorsAugust 9th, 2024
Extended LND During Radical Cystectomy Offers No Overall Survival EdgeApril 7th, 2023
Join now to see all

Grant Support

P-2: The Effect Of RAD On Androgen Receptor Expression And Activity In ProstateNational Cancer Institute2010–2011
The Effect Of Radiation On Androgen Receptor Expression And Activity In ProstateNational Cancer Institute2007–2009